This Lucid Diligence Brief examines Erasca’s clinical collaboration with Bristol Myers Squibb (BMS), assessing whether combining ERAS-0015 with navlimetostat can deliver meaningful clinical benefit in MTAP-deleted pancreatic cancer, strengthen ERAS-0015’s position as a combination therapy backbone and establish a differentiated position in precision oncology.
Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.
Dive deeper
Seven questions, 60-second thesis frame.
What Changed: Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 in Pancreatic Cancer
On 17 November 2026, Erasca announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMS) to evaluate ERAS-0015, an investigational oral pan-RAS molecular glue, alongside navlimetostat (BMS-986504), an investigational PRMT5 inhibitor, in a Phase 1/2 study of MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). (Erasca announcement, Independent market-news summary)
BMS will sponsor the study; Erasca will supply ERAS-0015. Both retain development and commercial rights to their respective compounds. The collaboration is mutually non-exclusive, with no financial consideration disclosed. (GlobeNewswire announcement)
60-Second Thesis: Can ERAS-0015 and Navlimetostat Deliver a Differentiated Combination?
The partnership strengthens external interest in ERAS-0015, but does not yet validate the combination clinically or commercially. The scientific rationale is plausible: MTAP deletion creates a PRMT5-associated vulnerability, while many pancreatic cancers remain dependent on oncogenic RAS signalling. Concurrent inhibition could produce complementary activity, but an acceptable therapeutic window and incremental efficacy must be demonstrated in patients. (Cancer Research review, 2026)
The more revealing context is portfolio strategy. On 4 November 2026, Erasca also announced a Phase 1/2 combination study with Tango Therapeutics’ PRMT5 inhibitor vopimetostat. Two PRMT5 partnerships offer optionality and complementary clinical learning, but neither establishes superiority. (Erasca news releases)
Confidence rises with durable responses, manageable overlapping toxicity and reproducible biomarker-defined benefit. Confidence falls if combination dosing compromises tolerability, efficacy is indistinguishable from the individual agents, or competing RAS/PRMT5 regimens advance faster.
Seven Diligence Questions for Erasca’s Bristol Myers Squibb Collaboration
Clinical
- Can dual RAS/PRMT5 inhibition deliver incremental benefit? What response rate, duration of response and progression-free survival would distinguish the combination from single-agent activity and available PDAC regimens?
- Is the therapeutic window sufficiently wide? Can investigators achieve meaningful exposure to both drugs without unacceptable haematologic, gastrointestinal or other overlapping toxicities? Historic PRMT5 inhibition has faced dose-limiting haematologic toxicity. (Cancer Research review)
Payer or Access
- How precisely will the eligible population be defined? Will selection require tissue-confirmed homozygous MTAP deletion, a qualifying RAS mutation, or both, and how consistently can these be identified through routine genomic profiling?
- What evidence would unlock reimbursement? Will an eventual programme need randomized survival benefit, meaningful quality-of-life improvement and a validated genomic-testing pathway to justify combination pricing?
Ops or Adoption
-
Can two organisations execute a coordinated development plan? Who controls dose selection, biomarker assays, data disclosure, regulatory interactions and expansion decisions under a BMS-sponsored, mutually non-exclusive agreement? (Erasca announcement)
Competitive
-
What makes this combination differentiated? Navlimetostat is already being evaluated with other therapies, including daraxonrasib, in the MountainTAP-5 programme. How will ERAS-0015 distinguish itself against alternative RAS/PRMT5 combinations? (ClinicalTrials.gov, NCT07492680)
Team or Cap table
- How much value can Erasca actually capture? With each company retaining its own compound rights, what are the economic benefits of the trial, follow-on development obligations, manufacturing commitments and implications for Erasca’s freedom to operate?Erasca reported approximately $948 million of cash, cash equivalents and marketable securities at 30 September 2026, but the collaboration announcement did not disclose a new upfront payment. (Erasca Q3 2026 results, Collaboration announcement)
Erasca–Bristol Myers Squibb Collaboration: Key Risks and Red Flags
-
No demonstrable added efficacy: The combination produces responses no more compelling than relevant monotherapy benchmarks, after accounting for population and trial-design differences.
-
Intolerable combination dosing: Toxicity-driven dose reductions or discontinuations prevent sustained biologically effective RAS and PRMT5 inhibition.
-
Weak strategic defensibility: Competing regimens achieve better clinical evidence, or intellectual-property disputes restrict ERAS-0015 development. Erasca specifically identifies litigation involving Revolution Medicines in its risk disclosures. (Erasca collaboration release)
What to Watch Next: ERAS-0015 Clinical Data and RAS/PRMT5 Combination Development
Erasca virtual investor event, 8:00 a.m. ET / 1:00 p.m. GMT.
Updated AURORAS-1 Phase 1 ERAS-0015 data following the 18–20 November ENA symposium. This is a monotherapy evidence catalyst, not a readout of the new BMS combination. (Official event notice)
Evidence limitation: The collaboration release does not establish a trial-specific efficacy endpoint, start date or numerical response target for the BMS combination. The clinical rationale is independently supported, but the incremental benefit remains unproven. Independent reporting of the announcement is primarily syndicated or summary coverage, rather than substantive third-party clinical assessment.
Competitive intelligence: the benchmark that matters
On 9 November 2026, Tango Therapeutics reported an 82% objective response rate and 88% nine-month progression-free survival rate in efficacy-evaluable second- and third-line PDAC patients receiving vopimetostat plus daraxonrasib, based on an August 20 data cutoff. These are company-reported, early-phase, selected-cohort findings, not randomized comparative evidence. (Tango Q3 clinical update, SEC filing)
This creates a concrete benchmark for Erasca’s PRMT5 combinations. Any future comparison must account for treatment line, sample size, response evaluability and dosing, rather than comparing headline response rates directly.
FAQ: Erasca’s Collaboration with Bristol Myers Squibb
What changed in Erasca’s 17 November 2026 collaboration with Bristol Myers Squibb?
Erasca and BMS agreed to evaluate ERAS-0015 plus navlimetostat in a Phase 1/2 study of MTAP-deleted pancreatic cancer. BMS will sponsor the study while Erasca provides its investigational drug. The parties retain separate commercial rights, and the agreement does not establish clinical efficacy. (Erasca announcement)
Does Erasca’s 17 November 2026 BMS collaboration represent clinical validation of ERAS-0015?
No. It represents a decision to test a mechanistically plausible combination, not evidence that the regimen improves survival or response rates. ERAS-0015 already has an ongoing Phase 1 monotherapy programme, AURORAS-1, but its results cannot establish the efficacy of the new combination. (ClinicalTrials.gov, NCT06983743, Erasca announcement)
Why combine ERAS-0015 and navlimetostat following the 17 November 2026 announcement?
The approach targets two vulnerabilities: RAS signalling and PRMT5 dependence associated with MTAP loss. Navlimetostat has already demonstrated antitumour activity in earlier MTAP-deleted cancer studies, although the benefit from combining it with ERAS-0015 remains unknown. (AACR navlimetostat abstract, 2026, Cancer Research review)
What safety issues matter after Erasca’s 17 November 2026 BMS announcement?
Combination treatment could introduce additive toxicities or require dose reductions. In previously reported navlimetostat monotherapy patients, 14% experienced grade 3 or higher treatment-related adverse events, but those findings do not establish the safety of the new dual-targeted regimen. Combination-specific dose intensity, discontinuations and adverse-event attribution will be critical. (AACR clinical abstract)
What is the regulatory and reimbursement outlook after Erasca’s 17 November 2026 collaboration announcement?
The BMS partnership involves investigational therapies and does not itself confer FDA approval or an established reimbursement pathway. Erasca previously reported FDA Fast Track designation for ERAS-0015 in metastatic pancreatic adenocarcinoma, which should not be interpreted as approval of the BMS combination. Future coverage will depend on the eventual label, evidence of clinical benefit, molecular testing requirements and payer policy. (Erasca Q3 results, Collaboration announcement)
Publisher / Disclosure
Publisher: LucidQuest Ventures Ltd. Produced: 18 Nov 2026, approximately 05:20 GMT, London. Purpose: general and impersonal information. Not investment research or advice. No offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is”, and may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts identified in preparation; authors’ holdings have not been independently verified. © 2026 LucidQuest Ventures Ltd.
Entities / Keywords
Erasca; Bristol Myers Squibb; ERAS; BMY; ERAS-0015; navlimetostat; BMS-986504; MRTX1719; Tango Therapeutics; vopimetostat; TNG462; Revolution Medicines; daraxonrasib; RMC-6236; pan-RAS; RAS/MAPK; PRMT5; MTAP deletion; MTA; synthetic lethality; pancreatic ductal adenocarcinoma; PDAC; NSCLC; AURORAS-1; NCT06983743; MountainTAP-5; NCT07492680; FDA; ClinicalTrials.gov; molecular diagnostics; companion diagnostics; CMS; US payers; reimbursement; precision oncology; Phase 1/2; clinical collaboration; intellectual property
